Monopar Therapeutics (MNPR) Current Assets (2016 - 2026)

Monopar Therapeutics has reported Current Assets for 10 years, with the latest figure at $140.5 million in Q4 2025.

• Quarterly Current Assets rose 132.97% year-over-year to $140.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $140.5 million (up 132.97% YoY) and the FY2025 annual result came in at $140.5 million, up 132.97% from the prior year.
• Current Assets eased to $140.5 million in Q4 2025 per MNPR's latest filing, from $144.1 million in the prior quarter.
• Over five years, Current Assets peaked at $144.1 million in Q3 2025 and troughed at $6.1 million in Q3 2024.
• A 5-year average of $33.5 million and a median of $17.3 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets plunged 44.31% in 2023, then soared 2273.95% in 2025.
• Over 5 years, Current Assets stood at $20.5 million in 2021, then tumbled by 35.84% to $13.2 million in 2022, then slumped by 44.31% to $7.3 million in 2023, then surged by 722.24% to $60.3 million in 2024, then soared by 132.97% to $140.5 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $140.5 million, $144.1 million, and $53.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.